IV Ketamine Therapy
A New Paradigm in Mental Health Treatment
When traditional antidepressants fail, IV ketamine offers hope. This rapidly-acting treatment works through an entirely different mechanism than conventional psychiatric medications, often providing relief within hours rather than weeks.
What is IV Ketamine?
Ketamine is an NMDA receptor antagonist that was originally developed as an anesthetic in the 1960s and has been safely used in medical settings for over 50 years. At sub-anesthetic doses (much lower than used for anesthesia), ketamine demonstrates powerful rapid-acting antidepressant and anxiolytic effects.
Unlike traditional antidepressants that modulate serotonin, norepinephrine, or dopamine, ketamine works primarily through the glutamate system—the brain's most abundant excitatory neurotransmitter. By blocking NMDA receptors, ketamine triggers a cascade of neurobiological changes that promote synaptic plasticity, neurogenesis, and restoration of neural circuits disrupted by chronic stress and depression.
The American Psychiatric Association (APA) recognizes ketamine as an evidence-based treatment option for treatment-resistant depression, and research published in JAMA Psychiatry, The American Journal of Psychiatry, and Nature has documented its efficacy across multiple psychiatric conditions.
How IV Ketamine Works
Understanding the neurobiology behind rapid antidepressant effects
NMDA Receptor Antagonism
Ketamine blocks NMDA (N-methyl-D-aspartate) receptors, particularly on GABAergic interneurons. This blockade leads to a disinhibition of pyramidal neurons and a surge in glutamate release. The resulting activation of AMPA receptors triggers downstream signaling cascades involving BDNF (brain-derived neurotrophic factor) and mTOR (mammalian target of rapamycin) pathways.
This process promotes synaptogenesis—the formation of new synaptic connections—in prefrontal cortical regions that have been shown to atrophy in chronic depression. Functional MRI studies demonstrate restoration of connectivity in neural circuits critical for mood regulation, emotional processing, and cognitive function.
Rapid Neuroplasticity
Traditional antidepressants require weeks to months to induce neuroplastic changes. Ketamine's effects on synaptic plasticity occur within hours. Research using two-photon imaging in animal models has shown that ketamine triggers rapid spinogenesis—the growth of dendritic spines—within 24 hours of administration.
These structural changes correlate with antidepressant behavioral effects and persist for days to weeks after a single dose. The rapid restoration of synaptic density in the prefrontal cortex is thought to underlie ketamine's fast-acting antidepressant properties and its unique ability to rapidly reduce suicidal ideation.
The Glutamate Hypothesis of Depression
For decades, psychiatric treatment focused on the monoamine hypothesis—the idea that depression results from deficiencies in serotonin, norepinephrine, or dopamine. Ketamine's success has shifted paradigms toward the glutamate hypothesis, which posits that disrupted glutamate neurotransmission and impaired synaptic plasticity are central to depressive pathophysiology.
This represents a fundamental reconceptualization of how we understand and treat depression, opening new avenues for rapid-acting antidepressant development beyond ketamine itself.
Conditions Treated with IV Ketamine
Evidence-based applications supported by peer-reviewed research
Treatment-Resistant Depression
ICD-10: F32.9, F33.2
The most extensively researched application. Defined as major depressive disorder (MDD) that has not adequately responded to at least two different antidepressant trials. Meta-analyses show 50-70% response rates and 30-40% remission rates after a series of ketamine infusions. Effects can be observed within hours to days, making it invaluable for severe cases.
Suicidal Ideation
ICD-10: R45.851
Multiple randomized controlled trials demonstrate rapid reduction in suicidal thoughts, often within 24 hours. A 2018 study in American Journal of Psychiatry found significant decreases in suicide ideation scores at 24 hours post-infusion. Particularly valuable in acute crisis situations when patient safety is paramount.
Post-Traumatic Stress Disorder
ICD-10: F43.10
Emerging evidence supports ketamine for PTSD, particularly when combined with psychotherapy. Research published in JAMA Psychiatry (2021) demonstrated significant reductions in PTSD symptom severity. Ketamine may facilitate fear extinction and reconsolidation processes when paired with trauma-focused therapy.
Severe Anxiety Disorders
ICD-10: F41.1, F41.0
Studies show ketamine reduces anxiety symptoms in generalized anxiety disorder (GAD), social anxiety, and panic disorder. While research is less extensive than for depression, clinical experience demonstrates significant anxiolytic effects, particularly for anxiety comorbid with depression.
Obsessive-Compulsive Disorder
ICD-10: F42.2
Preliminary research indicates ketamine may be effective for treatment-resistant OCD. A 2013 study in Biological Psychiatry found rapid reductions in obsessions and compulsions following ketamine infusion. Particularly promising for patients who have not responded to SSRIs and exposure-response prevention therapy.
Chronic Pain Syndromes
ICD-10: G89.29, M79.7
Ketamine has demonstrated efficacy for neuropathic pain, complex regional pain syndrome (CRPS), and fibromyalgia. Pain and depression share overlapping neural circuits, and ketamine addresses both the sensory and affective components of chronic pain. Particularly valuable when pain and psychiatric symptoms co-occur.
Understanding Your Treatment Options
Both are ketamine-based therapies, but they differ in delivery, dosing, and clinical applications
Which Option is Right for You?
The choice between IV ketamine and Spravato depends on multiple factors including your specific diagnosis, insurance coverage, treatment history, and personal preferences. IV ketamine offers more precise dosing control and has broader research support for multiple conditions. Spravato has the advantage of FDA approval specifically for depression and may have better insurance coverage.
Our psychiatric team will conduct a comprehensive evaluation to determine which ketamine-based therapy is most appropriate for your unique clinical situation. Some patients may benefit from trying both modalities at different points in their treatment journey.
What to Expect During IV Ketamine Therapy
Initial Psychiatric Evaluation
Comprehensive assessment including psychiatric history, current symptoms, previous treatments, medical history, and medication review. We'll discuss whether IV ketamine is appropriate for your specific condition and create a personalized treatment plan. Pre-treatment screening includes vital signs, ECG if indicated, and relevant laboratory tests.
Pre-Treatment Preparation
Patients should not eat for 4 hours before treatment (clear liquids permitted up to 2 hours prior). Arrange transportation home as you cannot drive for 24 hours post-infusion. Wear comfortable clothing. Bring headphones if you wish to listen to music during the infusion (many patients find this enhances the experience).
The Infusion Session (40-60 minutes)
An IV line is placed, typically in the arm. Ketamine is administered via controlled infusion pump at a dose of 0.5-1.0 mg/kg over 40-60 minutes. Vital signs (blood pressure, heart rate, oxygen saturation) are monitored continuously. A medical professional remains present throughout the entire infusion. Most patients recline in a comfortable chair in a quiet, calming environment.
Common experiences during infusion: Mild dissociation, relaxation, altered sensory perception, dream-like state. These effects are temporary and resolve shortly after the infusion ends.
Post-Infusion Monitoring (30-60 minutes)
After the infusion completes, patients rest in our recovery area while dissociative effects subside. Most patients feel back to baseline within 30-60 minutes. We reassess vital signs and ensure you're stable before discharge. You'll be released to your arranged transportation.
Induction Series (6 Infusions)
Standard protocol involves 6 infusions over 2-3 weeks, typically administered 2-3 times per week. This loading phase maximizes the likelihood of sustained response. Most patients begin experiencing symptom improvement after 2-3 infusions, with continued benefit accruing throughout the series.
Maintenance Phase
After completing the induction series, maintenance infusions are scheduled based on individual response. Some patients maintain remission for months after the initial series; others benefit from boosters every 2-6 weeks. We work collaboratively to find your optimal maintenance schedule, monitoring symptom scales and adjusting frequency as needed.
Integration with Ongoing Psychiatric Care
IV ketamine is most effective when integrated with comprehensive psychiatric treatment. We encourage continuation of psychotherapy during ketamine treatment, as emerging evidence suggests ketamine may enhance the efficacy of psychotherapy by increasing neuroplasticity and openness to new perspectives. Existing psychiatric medications are typically continued during ketamine treatment, though adjustments may be made based on response.
Side Effects and Safety Considerations
Common Side Effects (During/Immediately After Infusion)
- • Dissociation: Feeling detached from surroundings or body; altered perception of time/space (typically mild and not distressing)
- • Blood pressure elevation: Transient increase during infusion (monitored continuously)
- • Nausea: Occurs in 10-30% of patients (pre-treatment anti-nausea medication available)
- • Dizziness: Common but resolves within 1-2 hours
- • Anxiety during infusion: Uncommon; can be managed by slowing infusion rate
- • Headache: May occur post-treatment; typically mild
All acute effects resolve within 1-2 hours of infusion completion.
Contraindications and Precautions
- ⚠ Uncontrolled hypertension: Ketamine can elevate BP; must be controlled before treatment
- ⚠ Unstable cardiovascular disease: Recent MI, unstable angina, uncompensated heart failure
- ⚠ History of psychosis: May exacerbate psychotic symptoms; requires careful risk-benefit analysis
- ⚠ Active substance use disorder: Ketamine has abuse potential; active addiction is relative contraindication
- ⚠ Pregnancy: Safety not established; generally avoided unless benefits clearly outweigh risks
- ⚠ Severe liver disease: Ketamine is metabolized hepatically; use with caution
Long-Term Safety
When administered at appropriate doses under medical supervision, ketamine has an excellent long-term safety profile. Concerns about bladder toxicity (cystitis) are associated with chronic high-dose recreational use, not medical ketamine therapy. Regular monitoring ensures safety throughout treatment.
Insurance Coverage and Costs
Understanding Insurance Coverage
IV ketamine for psychiatric conditions is considered "off-label" use, which affects insurance coverage. While ketamine itself is FDA-approved as an anesthetic, its use for depression, PTSD, and other psychiatric conditions has not received specific FDA approval (unlike Spravato/esketamine).
Insurance Scenarios:
- Medication cost: Some insurers cover the ketamine medication itself
- Infusion service: Often not covered; considered investigational or experimental
- Out-of-network benefits: May provide partial reimbursement if you have out-of-network coverage
- Prior authorization: Some plans require extensive documentation of treatment resistance
Self-Pay Investment
Most patients pay out-of-pocket for ketamine infusions. Typical costs:
- Initial consultation: $300-$500
- Single infusion: $400-$800
- Induction series (6 infusions): $2,400-$4,800
- Maintenance infusions: Same per-session rate
We provide detailed billing statements ("superbills") that you can submit to your insurance for potential out-of-network reimbursement. Our team will work with you to maximize insurance benefits where possible.
Payment Options
We accept:
- Credit cards (Visa, MasterCard, American Express, Discover)
- Health Savings Account (HSA) and Flexible Spending Account (FSA) cards
- Cash or check
- Payment plans for qualified patients (inquire about options)
Cost vs. Value Consideration
While IV ketamine requires out-of-pocket investment, consider the costs of ongoing depression: lost work productivity, relationship strain, diminished quality of life, and potential hospitalization. For many patients with treatment-resistant conditions, ketamine represents an opportunity to regain functionality and well-being when other treatments have failed.
We're committed to transparent pricing and will discuss all costs upfront during your consultation.
Frequently Asked Questions
IV ketamine uses racemic ketamine (a 50/50 mixture of S-ketamine and R-ketamine) administered intravenously, while Spravato (esketamine) is the S-enantiomer of ketamine delivered via nasal spray. Key differences:
- Dosing control: IV ketamine allows precise, continuous dosing; Spravato delivers fixed intermittent doses
- Research history: IV ketamine has 20+ years of psychiatric research; Spravato was approved in 2019
- FDA status: Spravato is FDA-approved for treatment-resistant depression; IV ketamine is used off-label
- Conditions treated: IV ketamine has broader research support for PTSD, OCD, anxiety, chronic pain
- Insurance: Spravato may have better insurance coverage, though both often require significant out-of-pocket costs
Both are effective; we'll help determine which is right for your situation.
Many patients experience initial symptom relief within hours to days after the first infusion, with peak effects typically occurring after 2-3 treatments. This is dramatically faster than traditional antidepressants, which can take 4-8 weeks to show effects.
Research indicates approximately 70% of patients with treatment-resistant depression respond to ketamine therapy. The antidepressant effects are mediated by rapid synaptogenesis—the growth of new neural connections—in brain regions affected by depression.
However, individual responses vary. Some patients notice immediate mood elevation, while others experience more gradual improvement throughout the induction series. The full therapeutic potential is typically realized after completing all 6 initial infusions.
The standard protocol consists of:
- Induction phase: 6 infusions over 2-3 weeks (typically 2-3 sessions per week)
- Maintenance phase: Individualized based on response, ranging from every 2-6 weeks
After the initial series, some patients achieve lasting remission and require infrequent boosters, while others benefit from regular maintenance. We track your symptoms using validated scales (PHQ-9, GAD-7, etc.) and adjust the frequency collaboratively.
There's no indefinite commitment—treatment duration is determined by your response and goals.
Insurance coverage for IV ketamine varies significantly. While ketamine itself is FDA-approved as an anesthetic, its use for depression and psychiatric conditions is considered off-label, which affects coverage.
Common scenarios:
- Some insurance plans may cover the medication cost but not the infusion service
- Out-of-network benefits may provide partial reimbursement
- Most patients pay out-of-pocket and submit for reimbursement
We provide detailed billing statements and documentation to support insurance claims. Our team will discuss your specific coverage during the consultation and help maximize potential reimbursement.
During infusion (temporary, resolve within 1-2 hours):
- Dissociation (feeling detached from surroundings)
- Altered perception of time and space
- Dizziness or lightheadedness
- Nausea (10-30% of patients; preventable with pre-medication)
- Temporary blood pressure elevation (monitored continuously)
Long-term side effects: With properly monitored treatment at appropriate doses, long-term side effects are rare. Concerns about bladder toxicity (ketamine cystitis) are associated with chronic recreational abuse at very high doses, not medical ketamine therapy.
All infusions are conducted under continuous medical supervision with vital sign monitoring to ensure safety.
Yes. Research demonstrates that ketamine can rapidly reduce suicidal ideation, often within hours. Studies published in the American Journal of Psychiatry show significant decreases in suicidal thoughts within 24 hours of treatment, with effects lasting days to weeks.
This rapid anti-suicidal effect appears to be independent of ketamine's antidepressant effects—meaning suicidal thoughts can improve even before overall depression lifts. This makes ketamine particularly valuable in acute crisis situations when patient safety is paramount.
Important: Ketamine should be part of comprehensive suicide prevention planning, not a standalone intervention. We integrate ketamine with safety planning, crisis resources, increased monitoring, and ongoing psychiatric care.
If you're experiencing suicidal thoughts, please call 988 (Suicide & Crisis Lifeline) or go to your nearest emergency room.
Ketamine does have abuse potential when used recreationally at high doses. However, medical ketamine therapy administered under professional supervision at controlled doses has very low addiction risk.
Key safety factors in medical use:
- Controlled dosing (much lower than recreational use)
- Intermittent administration (not daily use)
- Medical supervision and monitoring
- Screening for substance use history
- Structured treatment protocols
Research on medical ketamine for depression has not shown significant addiction development. We carefully screen patients and monitor for any signs of problematic use. Active substance use disorder is a relative contraindication requiring thorough risk-benefit analysis.
Yes, in most cases. Ketamine can be safely combined with most psychiatric medications including:
- SSRIs and SNRIs (antidepressants)
- Mood stabilizers
- Antipsychotics
- Anxiolytics (with some considerations for benzodiazepines)
Important note on benzodiazepines: Some research suggests benzodiazepines (Xanax, Klonopin, Ativan, Valium) may reduce ketamine's effectiveness by blocking the neuroplasticity mechanisms. We may recommend holding benzodiazepines on infusion days or tapering if clinically appropriate.
We conduct a comprehensive medication review during your initial evaluation and provide specific guidance for your medication regimen. Never stop medications without consulting your prescriber.
Before your appointment:
- Arrange transportation (you cannot drive for 24 hours after infusion)
- Avoid eating for 4 hours before treatment (clear liquids OK up to 2 hours prior)
- Wear comfortable, loose-fitting clothing
- Bring headphones if you'd like to listen to music (many patients find this enhances the experience)
- Plan to have the rest of the day free for rest and integration
Day of infusion:
- Take your regular medications unless specifically instructed otherwise
- Arrive 15 minutes early to complete any remaining paperwork
- Use the restroom before the infusion begins
- Set an intention or openness to the experience (many patients find this helpful)
After infusion: Rest at home, stay hydrated, avoid important decisions or stressful activities. Many patients benefit from journaling or quiet reflection.